HOME >> MEDICINE >> NEWS
More protests against abortion pill

Drug-induced abortion is now legal in the US, but there's a snag...

AFTER a ten-year fight, the "abortion pill" RU486 is finally available in the US. But the pill's supporters fear theirs may be a pyrrhic victory, because production of a second pill that has to be taken with RU486 is now under threat.

RU486 (mifepristone) was approved in Britain nine years ago as an alternative to surgical abortions in the first two months of pregnancy. But American anti-abortion campaigners fought bitterly against it. Now that the US Food and Drug Administration has approved mifepristone, attention has turned to misoprostol, a prostaglandin pill originally developed to treat gastric ulcers.

Supporters of RU486 told New Scientist that they fear anti-abortion campaigners will target misoprostol supply because, although it is officially produced to treat stomach ulcers, obstetricians use it to complete the abortion process started by RU486.

The Reverend Flip Benham, national director of Operation Rescue-one of the most powerful anti-abortion groups in the US-says any drug firms involved in pharmaceutical abortion will be targeted by his group. "If you're going to go ahead and make this pill, you better know that Christians in America do not want to buy pharmaceuticals from you."

RU486 blocks the action of the hormone progesterone, causing the lining of the uterus to break down. Taken two days later, misoprostol makes the uterus contract and the cervix dilate, helping to expel the embryo. But now it seems even the company that makes misoprostol is getting the jitters.

For years, obstetricians have used misoprostol to dilate the cervix during labour. But only when the FDA was about to approve its use with the abortion pill-following pressure from RU486 supporters-did the manufacturer, Pharmacia, send out a sternly worded letter warning against misoprostol's use during pregnancy. The drugs company insis
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
24-Oct-2000


Page: 1 2

Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. New study in Nature demonstrates protection against cell death during heart attack
3. Vaccine against childhood pneumonia shows promise
4. Mayo Clinic discovers new pathway against pancreatic cancer
5. Orthodontists must brace against back pain
6. NYUS Duster cautions against FDA approval of race-based pharmaceutical
7. Female sex hormones play a vital role in defense against sexually transmitted diseases
8. New European cancer figures for 2004 major efforts needed against the big four killers
9. New highly active agents against sandfly fever
10. New mosquito control strategy proves successful against dengue fever
11. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: More protests against abortion pill

(Date:7/28/2014)... (PRWEB) July 28, 2014 The Wireline Services ... market in Europe with analysis and forecast of revenue. The ... around $1.3 billion in 2013 to $2.4 billion by 2019, ... Browse through the TOC of the Wireline Services Market in ... provided. This also provides a glimpse of the segmentation in ...
(Date:7/28/2014)... 2014 The North America Carotenoids & Antioxidants ... in North America with analysis and forecast of revenue. This ... 2012 to $812.7 million by 2018, at a CAGR of ... of the North America Carotenoids & Antioxidants Market report to ... provides a glimpse of the segmentation in the market, and ...
(Date:7/28/2014)... (HealthDay News) -- A common inflammatory muscle disorder ... may increase the risk for heart attack and ... study found that patients with polymyalgia rheumatica are ... that affect the blood vessels. Doctors should carefully ... polymyalgia rheumatica to reduce their risk for complications, ...
(Date:7/28/2014)... The Oneida Indian Nation today announced ... of accompanying PGA TOUR players will be teeing up ... Begay III for the seventh annual Notah Begay III ... Casino ’s Atunyote® Golf Club on Wednesday, August 27, ... Dufner, Jimmy Walker, Jonas Blixt, Angel Cabrera and Louis ...
(Date:7/28/2014)... 2014A two-step decision tree analysis, incorporating Donabedian,s model, ... the many available quality standards, guidelines, recommendations and ... international quality standards for radiation therapy, according to ... of Practical Radiation Oncology (PRO), the ... for Radiation Oncology (ASTRO). , Guidelines, recommendations and ...
Breaking Medicine News(10 mins):Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 5Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3
(Date:7/28/2014)... 2014   Cardioxyl Pharmaceuticals, Inc. announced today ... CXL-1427, a novel potential treatment for acute decompensated heart ... company has now initiated dosing of hospitalized patients with ... designed to further evaluate the drug,s safety and tolerability ... Phase I clinical trial evaluated the safety and tolerability ...
(Date:7/28/2014)... 28, 2014  ProteinSimple announced today that it has ... new assay allows users to detect all proteins separated ... Western users can analyze proteins without the need for ... changed protein analysis as we know it today. First, the ... - no messy gels, no transfer tanks, no blots, ...
(Date:7/27/2014)... /PRNewswire-iReach/ -- This is a professional and ... Vardenafil (CAS 224785-90-4) industry. The report firstly ... 224785-90-4) including its classification, application and manufacturing ... China,s top manufacturers of Vardenafil (CAS 224785-90-4) ... cost, gross margin and market share etc. ...
Breaking Medicine Technology:Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2ProteinSimple Says "Never Run a Gel Again!" 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4
Cached News: